<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0001">
 <label>Table 1</label>
 <caption>
  <p>Results of randomized studies with specific therapeutic agents in hospitalized patients with COVID-19 (randomized evaluation of COVID-19 therapy: 
   <ext-link ext-link-type="uri" xlink:href="https://www.recoverytrial.net/results" id="interref0001" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.recoverytrial.net/results</ext-link>).
  </p>
 </caption>
 <alt-text id="alt0002">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top">Therapeutic agent</th>
    <th valign="top">Target</th>
    <th valign="top">Mechanism of action</th>
    <th valign="top">Study Design</th>
    <th valign="top">Primary endpoint: 28-day mortality</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top">Dexamethasone (Dexa)</td>
    <td valign="top">General inflammation</td>
    <td valign="top">A steroid</td>
    <td valign="top">Dexa: 6 mg po qd PO or IV, N =  2,104 Usual care: N =  4,321</td>
    <td valign="top">35% mortality reduction in ventilated patients (95% CI: 0.48-0.88)
     <break/>20% mortality reduction in those requiring oxygen (95% CI: 0.67-0.96)
     <break/>No benefit in those not requiring respiratory support
    </td>
   </tr>
   <tr>
    <td valign="top">Hydroxychloroquine (HCQ)</td>
    <td valign="top">Viral entry by endocytosis</td>
    <td valign="top">Impairs lysosome function</td>
    <td valign="top">HCQ: N = 1,542 Usual care: N = 3,132</td>
    <td valign="top">HCQ: 25.7% Usual care:23.5%
     <break/>Hazard ratio: 1.11 (95% CI: 0.98-1.26)
     <break/>
     <break/>No effect on hospital stay or other outcomes
    </td>
   </tr>
   <tr>
    <td valign="top">Loinavir-Ritonavir (L-R)</td>
    <td valign="top">Protease/cytochrome P450 inhibitors</td>
    <td valign="top">Viral replication</td>
    <td valign="top">L-R: N = 1,596 Usual care: N = 3,376</td>
    <td valign="top">L-R: 22.1%
     <break/>Usual care: 21.3%
     <break/>Relative risk: 1.04 (95%CI: 0.91-1.18)
     <break/>No benefit on secondary endpoints
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
